{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vanzacaftor", "query": { "intervention": "Vanzacaftor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T12:23:31.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05867147", "title": "An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Vanzacaftor", "type": "DRUG" }, { "name": "Vanzacaftor Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 56, "start_date": "2023-04-26", "completion_date": "2023-06-14", "has_results": false, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-09-06T12:23:31.533Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867147" }, { "nct_id": "NCT06154447", "title": "Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-828", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Tezacaftor", "type": "DRUG" }, { "name": "VX-118", "type": "DRUG" }, { "name": "Deutivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2023-12-12", "completion_date": "2026-07-10", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-06T12:23:31.533Z", "location_count": 12, "location_summary": "Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06154447" }, { "nct_id": "NCT07283770", "title": "Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-581", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "D-IVA", "type": "DRUG" }, { "name": "TEZ", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 136, "start_date": "2025-12-09", "completion_date": "2026-11-19", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-06T12:23:31.533Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07283770" }, { "nct_id": "NCT06299709", "title": "A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VNZ/TEZ/D-IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 34, "start_date": "2024-03-13", "completion_date": "2024-05-23", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-09-06T12:23:31.533Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299709" }, { "nct_id": "NCT06299696", "title": "A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VNZ/TEZ/D-IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "25 Years to 80 Years" }, "enrollment_count": 10, "start_date": "2024-03-26", "completion_date": "2024-04-16", "has_results": false, "last_update_posted_date": "2024-05-16", "last_synced_at": "2026-09-06T12:23:31.533Z", "location_count": 1, "location_summary": "Woburn, Massachusetts", "locations": [ { "city": "Woburn", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299696" }, { "nct_id": "NCT06683092", "title": "Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "RETRIAL-Mental Health", "type": "OTHER" }, { "name": "RETRIAL-Liver", "type": "OTHER" }, { "name": "RETRIAL-Neuro", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 200, "start_date": "2025-05-01", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-09-06T12:23:31.533Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06683092" }, { "nct_id": "NCT07349394", "title": "Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VNZ/TEZ/D-IVA", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 18, "start_date": "2026-01-12", "completion_date": "2026-03-12", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-09-06T12:23:31.533Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07349394" }, { "nct_id": "NCT05844449", "title": "Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VNZ/TEZ/D-IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 174, "start_date": "2023-08-11", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-06T12:23:31.533Z", "location_count": 18, "location_summary": "Orange, California • Palo Alto, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05844449" } ] }